Latest Whitepapers

This whitepaper explores how transitioning from RUO to cGMP chemicals can mitigate risks, streamline processes and maintain regulatory compliance, ultimately accelerating your journey from lab to clinic.

This whitepaper explores the latest advancements in OOC platforms that can help to efficiently simulate drug toxicity responses.

This article examines recent advancements in cell therapy research, from promising lab findings poised for clinical translation to enhancements in development, testing, and manufacturing processes.

This article explores new workflows using data-driven modeling to improve culture medium and new control algorithms allowing for better modulation within the bioprocess design space.

This article explores how quality control can improve protocol standardization, enhance scalability and ensure that cultures meet regulatory criteria.

The sensitivity and specificity of mass spectrometry (MS) has made it an indispensable tool for biopharmaceutical analysis, ensuring the safety and efficacy of biologics.

Due to the sheer number of possible compounds available, pharmaceutical companies have been adopting high-throughput screening (HTS) methods that can screen chemical libraries rapidly and inexpensively to identify the most promising compounds with activity against a specific biological target.

Innovative strategies to shorten the research and development cycle, increase process efficiency and expedite the drug discovery process are needed.

Binding affinity is a significant factor to consider. However, relying solely on affinity can be problematic, as the highest affinity mAbs may not exhibit optimal activity. To ensure the best lead candidates, it is crucial to consider factors like specificity, selectivity and biological relevance.

This whitepaper highlights how PFFs could become the breakthrough modeling platform for scientists to discover and develop the next therapeutic for neurodegenerative diseases.